KHK7791
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Mar 15, 2021 → Jun 27, 2022
NCT ID
NCT04771780About KHK7791
KHK7791 is a phase 3 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04771780. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 14 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (12)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04771780 | Phase 3 | Completed |
| NCT04766385 | Phase 3 | Completed |
| NCT03831607 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia